Pulmonary Arterial Hypertension: A Review in Pharmacotherapy

被引：14

作者：

Patel, Bhaumik B. ^{[1
]}

Feng, Ying ^{[1
]}

Cheng-Lai, Angela ^{[1
]}

机构：

[1] Montefiore Med Ctr, Dept Pharm, Bronx, NY 10467 USA

来源：

CARDIOLOGY IN REVIEW | 2015年 / 23卷 / 01期

关键词：

riociguat; macitentan; oral treprostinil; six-minute walk distance; ENDOTHELIN RECEPTOR ANTAGONIST; 6-MINUTE WALK DISTANCE; 5 INHIBITOR THERAPY; ORAL TREPROSTINIL; LONG-TERM; DOUBLE-BLIND; INHALED TREPROSTINIL; MACITENTAN; PHARMACOKINETICS; EPOPROSTENOL;

D O I：

10.1097/CRD.0000000000000042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pulmonary arterial hypertension (PAH) is a progressive disease that remains incurable. The past 2 decades have witnessed many advances in PAH-directed therapies. More recently, 3 new oral agents have become available in the United States within the past 2 years. Treprostinil is now available in extended-release oral tablets. Macitentan is the third endothelin receptor antagonist approved for use, demonstrating benefits on morbidity and mortality among patients with PAH in an event-driven study. Riociguat is the first soluble guanylate cyclase stimulator that has been approved for use in the United States. This article reviews the clinical efficacy and safety of these 3 agents and the roles they play in the management of PAH. Additionally, we review the limitations of using surrogate markers such as change in 6-minute walk distance to assess disease progression.

引用

页码：33 / 51

页数：19